N/A N=5,824 Comparison of Outcomes Between Parenteral and Enteral Nutrition
Deglutition Disorders
Primary: Mortality Calculated From Outcome Section From DPC Database at 90 Days — 359; 287 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=97,507 Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates
Neonatal Death · Prematurity
Primary: Use of Parenteral Nutrition (Project A) — 62145 Participants
Phase 4 N=94 Oral Nutrition After Regular Radical Cystectomy
Post Cystostomy
Primary: the Postoperative Length of Stay — 18; 14 day — p=<0.001
N/A N=1,059 Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients
Critically Ill
Primary: Percentage of Prescribed Calories From Energy — 32; 34.2; 43.6; 33.6 percentage of prescription
Phase 3 N=305 Impact of SPN on Infection Rate, Duration of Mechanical Ventilation & Rehabilitation in ICU Patients
Critically Ill
Primary: Documented Infection Rate — 58; 41 Infections
N/A N=484 Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)
Allogeneic Stem Cell Transplant · Graft Versus Host Disease · Hematologic Malignancy
Primary: Number of Participants With Acute Graft Versus Host Disease (GvHD) at Any Site (Grade II or Above) and Acute GvHD of the Gut of Any Grade — 75; 73; 31; 63 Participants
Phase 2 N=15 Use of Pancreatic Enzymes in Short Bowel Syndrome
Short Bowel Syndrome
Primary: Change in Coefficient of Fat Absorption — 2.3 percentage of fat absorbed
Phase 3 N=2 Use of Omegaven for Treatment With Parenteral Nutrition Associated Liver Disease
Parenteral Nutrition-related Hepatitis
Primary: Disease Progression as Measured by Serum Levels of Hepatic Enzymes
Phase 3 N=2 Omegaven as Alternative Parenteral Fat Nutrition
Cholestasis · Cholestasis of Parenteral Nutrition
Primary: Number of Participant With Decrease in Direct Bilirubin Level — 2; 0 Participants
Phase 4 N=74 The HOME Study (HPN With OMEGA-3)
Patients Requiring Home Parenteral Nutrition
Primary: Change of Liver Function Parameters From Baseline to Visit 2 — 0.0606; -0.0703 normalized sum- no unit — p=0.025
N/A N=170 TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients
Hyperglycemia
Primary: Mortality — 36 mortality rate
N/A N=2,410 Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines
Acute Respiratory Failure · Shock
Primary: Mortality — 422; 443 Participants
N/A N=119 Individualized Nutrition for Adult Recipients of Allogeneic Stem Cell Transplants - Effect on Quality of Life
Effect of Individualized Nutrition on Quality of Life
Primary: Global Quality of Life Score — 58.8; 55.4 units on a scale
Phase 3 N=86 Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
Short Bowel Syndrome
Primary: Responder — 27; 13 subjects — p=0.002
N/A N=129 Parenteral Hydration in Advanced Cancer Patients
Advanced Cancer · Dehydration
Primary: Participant Reduced Symptom Burden — -3.3; -2.8 units on a scale
Phase 3 N=100 Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN
Parenteral Nutrition
Primary: Number of New Nosocomial Infections After 48 Hrs of Parenteral Nutrition (PN) Between the 2 Groups During Their Hospital Stay — 21; 29 number of nosocomial infections
Phase 2 N=11 Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury
Total Parenteral Nutrition-induced Cholestasis
Primary: Number of Participants With Normalization of Direct Bilirubin — 11 participants
N/A N=136 Low Dose Parenteral Fat for Prevention of Parenteral Nutrition Associated Cholestasis in Preterm Neonates
Parenteral Nutrition-Associated Liver Disease
Primary: The Presence of Cholestasis at Age of 28 Days or When Full Enteral Nutrition is Achieved, Whichever is Longer. — 39; 45 participants who developed Cholestasis
N/A N=40 A More Physiological Feeding Process in ICU:the Intermittent Infusion With Semi-solidification of Nutrients
Nutrition, Enteral
Primary: the Ratio of the Enteral Nutrition — 0.98; 0.73 ratio
N/A N=124 Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
Gastrointestinal Hemorrhage · Clostridium Difficile Colitis
Primary: Number of Subjects With GI Bleeding — 1; 1 participants
Phase 4 N=303 Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils
Obstruction · Cancer · Ileus
Primary: Prealbumin — 0.15; 0.16 g/l
N/A N=293 Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants
Cholestasis · Cholestasis of Parenteral Nutrition
Primary: Time to Resolution of Parenteral Nutrition Associated Cholestasis Prior to End of Study — 38.02 Days
Phase 3 N=23 Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
Urea Cycle Disorders
Primary: Adverse Events — 0; 6 participants
N/A N=100 Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation
Haematological Malignancy
Primary: The Between-group Change for Body Weight — -4.0; -3.4 kilogram — p=0.24
N/A N=671 Prevention of Peritonitis in Peritoneal Dialysis
Kidney Failure, Chronic · Peritoneal Dialysis-associated Peritonitis · Dialysis Capd Infection
Primary: Time to the First Dialysis-associated Peritonitis Episode in the Retraining Group and the Control Group — 381; 368 Days to first peritonitis episode — p=0.51
N/A N=100 Clinical Experience With Numeta in Preterm Infants
Premature Infants
Primary: Protein — 3.1; 3.6 g/kg/d
N/A N=34 COPD: Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks.
Malnutrition
Primary: Weight Changes — 2.3; 4.4 kg
N/A N=64 Treatment of Peritonitis in Automated Peritoneal Dialysis
Secondary Peritonitis
Primary: Peritonitis Resolved — 26; 29 participants — p=<0.05
N/A N=40 Personalized Nutrition Delivery to Improve Resilience in Older Adult Trauma Patients
Trauma · Critical Illness
Primary: Number of Patients Recruited — 28; 12 Participants
Phase 2 N=72 Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis
Parenteral Nutrition Associated Liver Disease PNALD · Cholestasis
Primary: Number of Patients With Progression to Small Bowel Transplantation. — 19 Participants